IL-4R Antagonist Enhances SCIT Efficacy and Safety
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current allergen-specific immunotherapy methods, such as subcutaneous immunotherapy (SCIT), face challenges with variable efficacy, adverse reactions, and the need for prolonged treatment duration, along with the risk of severe hypersensitivity reactions, highlighting the need for improved safety and tolerability.
Innovation Solution
Administering an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody, in combination with SCIT to inhibit allergen-specific IgE increase, enhance the ratio of IgG4 to IgE, and facilitate the administration of maintenance doses, thereby reducing the use of rescue medications like epinephrine and steroids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If allergen-specific immunotherapy is administered to treat allergy, then long-lasting protection and immune tolerance are achieved, but adverse reactions and severe hypersensitivity occur in 40-50% of patients
Solution Approach 1:
The patent introduces IL-4R antagonist as an intermediary agent that mediates between the allergen immunotherapy and the patient's immune system. The antagonist blocks the IL-4 signaling pathway, which is responsible for driving IgE production and allergic responses, thereby reducing adverse reactions while preserving the beneficial immunomodulatory effects of immunotherapy
Solution Approach 2:
The patent applies preliminary anti-action by administering IL-4R antagonist before or during allergen immunotherapy to preemptively block the harmful IL-4 signaling pathway. This preliminary blockade prevents the development of IgE-mediated allergic responses while allowing the immunotherapy to proceed, thus mitigating adverse reactions before they can occur
2Reliability
If increasing doses of allergen are administered during SCIT up-titration, then immune tolerance is induced, but the risk of severe hypersensitivity reactions increases
Solution Approach 1:
IL-4R antagonist serves as a protective intermediary during the up-titration phase, blocking the IL-4 signaling pathway that would otherwise amplify allergic responses to increasing allergen doses. This allows safer dose escalation while maintaining immunotherapy efficacy
Solution Approach 2:
The patent applies beforehand cushioning by pre-administering IL-4R antagonist to cushion or buffer against potential severe hypersensitivity reactions during up-titration. The antagonist creates a protective effect that absorbs or mitigates the harmful effects of increasing allergen exposure
3Reliability
If SCIT is administered to achieve symptom amelioration, then long-lasting protection is obtained, but treatment takes at least 3 years to induce immune tolerance
Solution Approach 1:
The patent applies parameter changes by modifying the immunological parameters through IL-4R antagonism. By blocking IL-4 signaling, the treatment shifts the immune response parameters toward reduced IgE production and enhanced IgG4 production, accelerating the induction of immune tolerance and shortening treatment duration
Data Source
AI summary
Methods for enhancing the efficacy, safety, and/or tolerability of a grass allergen-specific subcutaneous immunotherapy (SCIT) regimen in a subject having a grass allergy are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.